. 2021 Dec 9;101(3):101656. doi: 10.1016/j.psj.2021.101656

Table 3.

Body weight gain (BWG) and histomoniasis-related mortalities during Vaccination Phase (Experiment 2).¹^,²

Group³	Mortality	BWG (g)
Group³	Mortality	d 0–7	d 7–14	d 14–21	d 0–21
V-PC Cloacal 200k	8/36 (22.2%)	67 ± 3.94^bc	99 ± 7.17^b	-	-
Vacc Oral 2k	1/36 (2.78%)^*	70 ± 3.61^abc	112 ± 6.09^ab	202 ± 6.60^abc	401 ± 14.7^abc
Vacc Oral 20k	1/38 (2.63%)^*	81 ± 2.61^ab	133 ± 4.05^a	210 ± 6.86^ab	430 ± 7.73^ab
Vacc Cloacal 2k	0/36 (0.00%)^*	81 ± 2.38^ab	116 ± 5.51^ab	195 ± 7.27^abc	397 ± 14.6^abc
Vacc Cloacal 20k	2/37 (5.41%)^*	84 ± 3.73^a	133 ± 4.26^a	213 ± 6.05^a	440 ± 11.4^a
Vacc Cloacal 200k	1/30 (3.33%)^*	58 ± 3.61^c	119 ± 5.76^ab	181 ± 7.35^bc	373 ± 14.1^bc
NC	0/34 (0.00%)^*	76 ± 3.80^ab	110 ± 7.27^ab	181 ± 6.77^c	366 ± 14.6^c

^a-c

BWG data are expressed as mean ± SE; Values within a column with no common superscript differ significantly (P < 0.05). Data were analyzed using JMP Pro 16 ANOVA, further separated by Tukey's HSD.

Vaccination Phase began on d0 with administration of respective dose and route of either Vacc Buford P80a or Buford WTH cells/turkey.

The PC was terminated on d15 for lesion scores.

V-PC = Vaccination Phase positive-challenged control; Vacc = live-attenuated Histomonas meleagridis; NC = non-challenged control; WTH = wild-type H. meleagridis.

^⁎

Indicates significant difference in mortalities (P < 0.05) as compared to V-PC Cloacal 200k with chi-square test.